Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Apatinib Combined With PLD vs PLD for Platinum-resistant Recurrent Ovarian Cancer(APPROVE): a Randomized, Controlled, Open-label, Phase 2 Trial

NCT04348032 is registered in ClinicalTrials.gov with Chinese Academy of Medical Sciences as lead sponsor.

NCT NCT04348032
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04348032 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Apatinib Combined With PLD vs PLD for Platinum-resistant Recurrent Ovarian Cancer(APPROVE): a Randomized, Controlled, Open-label, Phase 2 Trial
Lead sponsor
Chinese Academy of Medical Sciences
Phase
Phase 2
Overall status
Unknown status
Start date
March 22, 2018
Completion date
June 30, 2022
Enrollment
152 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

platinum-resistant recurrent ovarian cancer